Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for the 2015 Times Higher Education (THE) Award for the ‘International Collaboration of the Year’.

The award recognises “exceptional projects carried out jointly between a UK institution and one or more international partners”. 

WWARN is a collaborative research network that works to provide the information necessary to prevent or slow antimalarial drug resistance, in turn, reducing the number of people falling ill and dying from malaria. Based at the University of Oxford, WWARN works with over 250 collaborators across the world.

Read more (Worldwide Antimalarial Resistance Network website)

Similar stories

MRC HIU appoints new Director

Awards and Appointments General

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

New Year's Honours 2021

Awards and Appointments General

Members of the Medical Sciences Division have been recognised in the New Year's Honours list for 2021.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards and Appointments General

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

Awards and Appointments General

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards and Appointments General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.